Litigation Details for KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd. (D. Mass. 2021)
✉ Email this page to a colleague
KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd. (D. Mass. 2021)
Docket | ⤷ Try a Trial | Date Filed | 2021-08-03 |
Court | District Court, D. Massachusetts | Date Terminated | 2023-01-23 |
Cause | 15:1 Antitrust Litigation | Assigned To | Richard Gaylore Stearns |
Jury Demand | Plaintiff | Referred To | |
Patents | 6,414,016; 6,583,174; 6,982,283; 7,064,148; 7,417,067; 7,795,312; 8,026,393; 8,071,613; 8,088,934; 8,097,649; 8,097,653; 8,114,890; 8,338,639; 8,389,542; 8,748,481; 8,779,187 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd.
Details for KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd. (D. Mass. 2021)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-09-20 | 11 | Amended Complaint | 6,414,016 (the “‘016 patent”); 8,071,613 (the “‘613 patent”); and …developing patent portfolios for their profitable drugs. 25. The first patent or patents in a branded…earlier-obtained patents. These narrower, later- obtained patents reflect, correspondingly, patents that are …challenge patents ostensibly covering the branded drug. A patent infringement lawsuit by the patent holder…The ‘858 patent was the Amitiza drug substance, or compound, patent and the strongest patent in the | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |